Device Trial Radar · NCT07951723
Enhanced Expiratory Rebreathing Space Therapy for Complex Sleep Apnea in Patients With Cardiovascular Disease
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Nov 15, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Chinese Pulmonary Vascular Disease Research GroupAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 20, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the effectiveness and safety of enhanced expiratory rebreathing space (EERS) therapy compared with conventional automatic positive airway pressure (APAP) therapy in patients with cardiovascular disease and complex sleep apnea (CompSA). This is a prospective, single-center, randomized controlled trial involving 40 participants aged 18-75 years. Eligible participants will be randomly assigned to either the EERS group or the conventional APAP group in a 1:1 ratio. Participants in the EERS group will receive individualized EERS therapy guided by overnight sleep monitoring, while those in the control group will receive conventional APAP therapy. Each participant will be followed for five weeks, including a one-week screening period, a two-week treatment period, and a two-week follow-up period. The primary outcome is the apnea-hypopnea index (AHI), which measures the number of breathing interruptions per hour of sleep, assessed after two weeks of treatment. Additional outcomes include other sleep-related breathing measures, cardiovascular health indicators, treatment adherence, comfort, and adverse events. The findings may help determine whether EERS therapy is an effective and safe treatment option for complex sleep apnea in patients with cardiovascular disease.
Conditions
- Complex Sleep Apnea
- Cardiovascular Diseases (CVD)
Interventions
Enhanced Expiratory Rebreathing Space (EERS) TherapyDevice
Participants will undergo individualized manual continuous positive airway pressure (CPAP) titration under overnight polysomnographic (PSG) monitoring. An enhanced expiratory rebreathing space (EERS) device will be connected between the patient interface and a single-level CPAP device to increase expiratory carbon dioxide rebreathing and stabilize respiratory control. End-tidal carbon dioxide (EtCO₂) will be monitored throughout titration. CPAP pressure will initially be set at 4-6 cmH₂O and manually adjusted by trained sleep technicians in increments of 1-2 cmH₂O to eliminate obstructive respiratory events. The lowest effective pressure will be selected for subsequent treatment. Participants will then receive home-based CPAP therapy combined with EERS for two weeks.
Automatic Positive Airway Pressure (APAP) TherapyDevice
Participants will undergo conventional automatic positive airway pressure (APAP) titration during overnight sleep monitoring using a single-level noninvasive positive airway pressure device and a nasal or oronasal mask. The initial pressure range will be set at 4-18 cmH₂O. The device will automatically adjust airway pressure in response to obstructive respiratory events, including apnea, hypopnea, snoring, and airflow limitation. Sleep technicians will monitor respiratory signals, oxygen saturation, mask leakage, and treatment tolerance. Individualized treatment settings will be determined based on overnight titration results, followed by two weeks of home-based positive airway pressure therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Apnea-Hypopnea Index (AHI) After Two Weeks of TreatmentTime frame: 2 weeks after initiation of treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.